|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:lorlatinib
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
L01ED10
|
|
gptkbp:brand
|
gptkb:Lorbrena
|
|
gptkbp:CASNumber
|
1454846-35-5
|
|
gptkbp:chemicalFormula
|
C21H19FN6O2
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
kinase inhibitor
|
|
gptkbp:form
|
gptkb:tablet
100 mg
25 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lorviqua
|
|
gptkbp:indication
|
ALK-positive metastatic non-small cell lung cancer
ROS1-positive metastatic non-small cell lung cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
ALK inhibitor
ROS1 inhibitor
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:familial_hypercholesterolemia
diarrhea
edema
hypertension
weight gain
peripheral neuropathy
cognitive effects
arthralgia
hypertriglyceridemia
mood effects
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:lorlatinib
|
|
gptkbp:bfsLayer
|
6
|